Target | cis/trans | Study | SNP | SNP location | Maj/min allele | MAF | N | βinv | seinv | Pinv | fclog | Plog | Praw |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IMDH1 | trans | Discovery | rs1354034 | 3:56,849,749 | C/T | 0.38 | 995 | -0.328 | 0.045 | 5.4×10-13 | -1.130 | 1×10-10 | 0.002 |
IMDH1 | trans | Replication | rs1354034 | 3:56,849,749 | A/G | 0.47 | 337 | 0.127 | 0.066 | 0.058 | 1.050 | 0.171 | 0.692 |
DLRB1 | trans | Discovery | rs1354034 | 3:56,849,749 | C/T | 0.38 | 995 | -0.294 | 0.044 | 6.1×10-11 | -1.110 | 7.5×10-11 | 6.7×10-7 |
DLRB1 | trans | Replication | rs1354034 | 3:56,849,749 | A/G | 0.47 | 337 | 0.120 | 0.045 | 0.009 | 1.110 | 0.005 | 0.004 |
AMPM2 | trans | Discovery | rs1354034 | 3:56,849,749 | C/T | 0.38 | 995 | -0.277 | 0.045 | 1.2×10-9 | -1.060 | 2.4×10-8 | 1.8×10-9 |
AMPM2 | trans | Replication | rs1354034 | 3:56,849,749 | A/G | 0.47 | 337 | 0.064 | 0.041 | 0.122 | 1.020 | 0.361 | 0.047 |
inverse-normalized probe levels | log2 transformed probe levels | raw probe levels | |
---|---|---|---|
Discovery study | |||
Replication study |
inverse-normalized probe levels | log2 transformed probe levels | raw probe levels | |
---|---|---|---|
Discovery study | |||
Replication study |
Target (abbrv.) | IMDH1 |
Target (full name) | Inosine-5'-monophosphate dehydrogenase 1 |
Somalogic ID (Sequence ID) | SL014735 (5229-90_3) |
Entrez Gene Symbol | IMPDH1 |
UniProt ID | P20839 |
UniProt Comment |
|
Targeted by drugs (based on IPA annotation) |
|
Target (abbrv.) | DLRB1 |
Target (full name) | Dynein light chain roadblock-type 1 |
Somalogic ID (Sequence ID) | SL011530 (3845-51_2) |
Entrez Gene Symbol | DYNLRB1 |
UniProt ID | Q9NP97 |
UniProt Comment |
|
Pathway Interaction Database |
|
Reactome |
|
Target (abbrv.) | AMPM2 |
Target (full name) | Methionine aminopeptidase 2 |
Somalogic ID (Sequence ID) | SL007261 (3170-6_1) |
Entrez Gene Symbol | METAP2 |
UniProt ID | P50579 |
UniProt Comment |
|
Targeted by drugs (based on IPA annotation) |
|
Biomarker applications (based on IPA annotation) |
|
All locus annotations are based on the sentinel SNP (rs1354034).
Download the detailed results of SNiPA's block annotation (PDF)
Genes hit or close-by |
|
Potentially regulated genes |
Trait | P | Study | Source |
---|---|---|---|
Mean platelet volume | 3×10-69 | 22139419 (PMID) | GWAS Catalog via SNiPA |
Mean platelet volume (MPV) | 3.3×10-69 | 22139419 (PMID) | GRASP2 nonQTL |
Platelet count (PLT) | 2.9×10-54 | 22139419 (PMID) | GRASP2 nonQTL |
Platelet counts | 3×10-54 | 22139419 (PMID) | GWAS Catalog via SNiPA |
Platelet count | 1.1×10-19 | 23263863 (PMID) | GRASP2 nonQTL |
Hematological traits (Red blood cell count, Hemoglobin concentration, Hematocrit, Mean corpuscular hemoglobin, MCH concentration, Mean corpuscular volume, Platelet count and White blood cell count) | 9.3×10-13 | 23263863 (PMID) | GRASP2 nonQTL |
This locus harbours a non-replicated trans-pQTL to Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1). Gieger et al. [PubMed] report this locus as a platelet count GWAS hit with ARHGEF3 (Rho Guanine Nucleotide Exchange Factor (GEF) 3) as functional gene. Gieger et al. showed that ablation of ARHGEF3 in D. rerio has profound effect on thrombopoiesis and erythropoiesis. Diseases associated with ARHGEF3 include osteoporosis. ARHGEF3 and IMPDH1 are functionally linked, since IMPDH1 catalyses the first step of the guanine ribonucleotide biosynthesis. This locus also has many trans-eQTLs (N=203); also trans-association with Dynein light chain roadblock-type 1 (DYNLRB1) and Methionine aminopeptidase 2 (METAP2) and several less significant associations. This locus also associates weakly in KORA with IMPDH2 (p=1.3×10-7).
The information gathered here is a result of an attempt to keep track of all interesting information that we encountered while investigating these loci. Please bear in mind that the annotation given here is neither complete nor free of errors, and that all information provided here should be confirmed by additional literature research before being used as a basis for firm conclusions or further experiments.